Therefore, in the future, it may be necessary to use multiple cell models combined with animal experiments to confirm the therapeutic effect of YCWLP on NASH, and to further confirm the role of SHP2 in the pathological mechanism of NASH (especially in terms of glucose homeostasis, insulin receptor signaling pathways, and stress response) and the therapeutic targets of YCWLP. This evidence concerns the gene INSR and metabolic dysfunction-associated steatohepatitis.